# Cardiometabolic Outcomes in Women With Overt Diabetes at Diagnosis Versus Gestational Diabetes: A Systematic Review and Meta-Analysis

**Authors:** Khadija Z Alkahtani, Muna M Mahjoub, Zainab M Takroni, Khadeeja K Ibrahim, Lian A Zeyad, Mohammed S Tayb, Mohammad A Alteibawi, Hadeel Almuzayen, Yosra M Sahl, Hanaa M Abd Rabeh, Nosaiba Z Ali, Manhal H Idris, Elaf M Abu-Aba, Shorooq M Alhousawi, Shatha Alqahtani

PMC · DOI: 10.7759/cureus.102898 · 2026-02-03

## TL;DR

Women diagnosed with overt diabetes during pregnancy face a much higher risk of developing type 2 diabetes and metabolic syndrome after childbirth compared to those with gestational diabetes.

## Contribution

This study provides the first meta-analysis comparing long-term cardiometabolic risks between overt diabetes in pregnancy and gestational diabetes.

## Key findings

- Women with overt diabetes had a 10.69 times higher risk of postpartum type 2 diabetes than those with gestational diabetes.
- Overt diabetes was associated with a more than two-fold increased risk of metabolic syndrome compared to gestational diabetes.
- The study found negligible heterogeneity in the risk of postpartum type 2 diabetes between the groups.

## Abstract

Women diagnosed with hyperglycemia in pregnancy represent a heterogeneous population. A distinct subgroup, those with overt diabetes or diabetes in pregnancy (DIP) diagnosed at the first prenatal visit or during pregnancy (fasting plasma glucose (FPG) ≥ 7.0 mmol/L or glycated hemoglobin (HbA1c) ≥ 6.5%), may carry a significantly higher long-term cardiometabolic risk than women with standard gestational diabetes mellitus (GDM). This study aimed to review and meta-analyse the risk of postpartum type 2 diabetes mellitus (T2DM), metabolic syndrome (MetS), and cardiovascular risk markers in women diagnosed with overt diabetes during pregnancy compared to those with GDM. PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library were searched from inception to December 2025. Observational studies comparing maternal postpartum cardiometabolic outcomes between women with overt diabetes (excluding known pre-existing diabetes) and women with GDM were included. Two independent reviewers extracted data and assessed quality using the Newcastle-Ottawa Scale and JBI checklists. Random-effects meta-analysis with Hartung-Knapp-Sidik-Jonkman adjustment was performed. The primary outcome was incident postpartum T2DM. Certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Seven studies (n = 3,293 participants) from Asia, Africa, Oceania, and Europe met the inclusion criteria. Women with overt diabetes had a substantially increased risk of developing postpartum T2DM compared to women with GDM (pooled odds ratio (OR) 10.69; 95% CI 5.32-21.48; p < 0.001; high certainty evidence). They exhibited a more than two-fold higher risk of MetS (OR 2.29; 95% CI 1.49-3.53; p < 0.001; moderate certainty evidence). Mean BMI was numerically higher in the overt diabetes group (mean difference 1.60 kg/m ²), though not statistically significant (p = 0.07). Heterogeneity was negligible for the primary outcome (I2 = 0.5%). These findings support the urgent need for stratified postpartum surveillance and intensive, early preventive interventions for women with overt diabetes, rather than managing them under general GDM protocols.

## Linked entities

- **Diseases:** type 2 diabetes mellitus (MONDO:0005148), metabolic syndrome (MONDO:0000816)

## Full-text entities

- **Diseases:** Hyperglycemia (MESH:D006943), MetS (MESH:D024821), dyslipidemia (MESH:D050171), beta-cell failure (MESH:D051437), Diabetes (MESH:D003920), GDM (MESH:D016640), obesity (MESH:D009765), retinopathy (MESH:D058437), stroke (MESH:D020521), metabolic dysregulation (MESH:D021081), metabolic disease (MESH:D008659), hyperglycemic (MESH:D006944), hypertension (MESH:D006973), myocardial infarction (MESH:D009203), HDP (MESH:D046110), CVD (MESH:D002318), vascular dysfunction (MESH:D002561), insulin resistance (MESH:D007333), T2DM (MESH:D003924), heart failure (MESH:D006333), adiposity (MESH:D018205), nephropathy (MESH:D007674), beta-cell dysfunction (MESH:D007340), coronary artery disease (MESH:D003324), gestational glucose intolerance (MESH:D018149), DIP (MESH:D011254), -cell (MESH:D002292)
- **Chemicals:** triglycerides (MESH:D014280), metformin (MESH:D008687), FPG (-), lipid (MESH:D008055), Glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12962184/full.md

---
Source: https://tomesphere.com/paper/PMC12962184